Stoneridge Investment Partners LLC Takes $123,000 Position in Immunome, Inc. (NASDAQ:IMNM)

Stoneridge Investment Partners LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,554 shares of the company’s stock, valued at approximately $123,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMNM. AQR Capital Management LLC lifted its position in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after purchasing an additional 4,129 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Immunome during the 3rd quarter worth $219,000. JPMorgan Chase & Co. lifted its holdings in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after buying an additional 1,520 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Immunome during the third quarter valued at about $363,000. Finally, MetLife Investment Management LLC increased its position in shares of Immunome by 129.1% during the third quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock worth $442,000 after acquiring an additional 17,053 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $10.87 on Friday. The company’s fifty day moving average is $11.21 and its two-hundred day moving average is $12.62. Immunome, Inc. has a 1-year low of $8.97 and a 1-year high of $30.96.

Analyst Ratings Changes

IMNM has been the topic of a number of recent analyst reports. Stephens began coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Monday, January 13th. Finally, Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $28.60.

Insider Buying and Selling

In other news, CTO Philip Tsai purchased 21,000 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were bought at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the purchase, the chief technology officer now owns 21,000 shares of the company’s stock, valued at $198,030. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 252,862 shares of company stock worth $2,140,545 over the last quarter. 8.60% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.